UNCY News

Unicycive Therapeutics, an early-stage biotech developing in-licensed therapies for kidney disease, raised $25 million by offering 5 million units at $5, the low end of the range of $5 to $6. Each unit consists of one share of common stock and four-fifths of a warrant, exercisable at $6.00. At pricing, the company commands a market value of $74 million. Unicycive originally filed...read more

Updated Monday, 7/12. After a slow holiday week, 15 IPOs are scheduled to raise nearly $4 billion in the week ahead. A handful of SPACs should also price. Italian drug container supplier Stevanato Group (STVN) plans to raise $900 million at a $6.8 billion market cap. Controlled by its founding family, the profitable company supplies glass vials,...read more

Unicycive Therapeutics, an early stage biotech developing in-licensed therapies for kidney disease, increased the proposed deal size for its upcoming IPO on Monday. The Los Altos, CA-based company now plans to raise $40 million by offering 6.7 million units at a price range of $5.50 to $6.50. Each unit contains one share of common stock and one-half of a warrant, exercisable at...read more

Updated Monday, 6/21/21. 17 IPOs are scheduled to raise $6.3 billion in the week ahead, led by two billion-dollar deals. Chinese freight platform Full Truck Alliance (YMM) plans to raise $1.5 billion at a $19.7 billion market cap. The company’s platform connects shippers with truckers to facilitate shipments across distance ranges, cargo weights,...read more